SAN FRANCISCO, CALIFORNIA, April 29, 2026
Laguna Biotherapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance for its lead candidate LGNA-100, a first-in-class live bacterial immunotherapy targeting high-risk pediatric leukemias. The FDA’s “safe-to-proceed” decision marks a critical transition for Laguna into a clinical-stage company, enabling the initiation of a Phase 1 first-in-human trial. Developed from the company’s proprietary QUAIL platform, LGNA-100 is designed to activate and expand γδ T cells, a specialized immune cell population capable of directly targeting and killing cancer cells, offering a novel therapeutic strategy for patients with limited treatment options and high relapse risk.
Novel Immunotherapy Harnesses γδ T Cell Activation
LGNA-100 represents a next-generation immunotherapy approach that leverages an attenuated live bacterial system derived from Listeria monocytogenes to stimulate the body’s innate immune response. Unlike conventional therapies that often rely on external immune modulation, this innovative platform is designed to activate endogenous γδ T cells, enhancing their ability to recognize and eliminate malignant cells while avoiding excessive immune exhaustion.
Preclinical findings highlighted in the company’s research demonstrate that LGNA-100 induces a multifunctional γδ T cell response with improved durability, kinetics, and functional activity, compared to earlier pharmacological activators. This targeted immune activation is particularly significant in the context of post-hematopoietic stem cell transplantation (HSCT), where γδ T cells play a key role in preventing leukemia relapse without triggering graft-versus-host disease, a major complication in transplant patients.
Phase 1 Trial Targets High-Risk Pediatric Leukemia
Advertisement
The upcoming Phase 1 clinical trial will be an open-label, dose-escalation study designed to evaluate the safety, tolerability, and mechanism of action of LGNA-100 in pediatric and young adult patients with high-risk acute leukemias and myelodysplastic syndromes (MDS). The study will focus on patients who have undergone αβ-depleted HSCT, a setting where relapse remains a major clinical challenge.
By administering LGNA-100 via intravenous infusion, researchers aim to validate the QUAIL platform’s ability to drive sustained immune activation and improve long-term outcomes. This first-in-human trial represents a critical milestone in translating decades of γδ T cell research into clinical application, with the potential to establish a new paradigm in cancer immunotherapy for pediatric oncology.
Advancing Oncology Innovation and Regulatory Milestones
The FDA IND clearance underscores Laguna’s commitment to rigorous scientific development and regulatory compliance, aligning with Good Clinical Practice (GCP) and early-stage clinical validation standards. This milestone also highlights the growing importance of novel immunotherapeutic platforms in addressing complex and treatment-resistant cancers, particularly in pediatric populations where therapeutic options remain limited. LGNA-100’s differentiated mechanism of action positions it as a highly innovative asset within the oncology pipeline, with potential applications beyond leukemia, including inflammatory and infectious diseases.
From a GxP perspective, the transition into clinical trials emphasizes the importance of data integrity, patient safety, and robust trial design, all of which are essential for advancing therapies through regulatory pathways. As Laguna progresses its clinical program, LGNA-100 could play a transformative role in reducing relapse rates and improving survival outcomes for patients with high-risk leukemia, reinforcing the company’s mission to deliver next-generation, system-level therapies for complex diseases.
Source: Laguna Biotherapeutics press release
